Cannasouth Trading Update

GENERAL
Tue, Jan 23 2024 03:50 pm

Cannasouth Limited (NZX:CBD), New Zealand’s first and largest listed medicinal cannabis company, is pleased to provide this trading update as the Group commences sales of its own-manufactured CBD oral solutions and dried cannabis flower products.

Group Revenues:
Oct-23 $26,000
Nov-23 $201,000
Dec-23 $243,000

Commercial sales of these products commenced in November 2023 following a lengthy verified process by the Medicinal Cannabis Agency. We are confident with the launch of our new products and expect ongoing revenue growth as clinics and prescribers obtain access to our product range either direct, or via wholesalers.

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas CEO / Executive Director
Email: [email protected]
Mobile: 021 484 649

Colin Foster
CFO / Company Secretary
Email: [email protected]
Mobile: 027 577 1498


Announcement PDF


Markets News

Infratil $480m injection prevents CDC devaluation
Infrastructure

Infratil $480m injection prevents CDC devaluation

The value of Infratil's holding has grown tenfold since acquisition. 

Markets

NZX flat on second trading day of 2025

The S&P/NZX 50 Index closed at 13,072.93, up 5.1 points or 0.039%.

Graham Skellern 06 Jan 2025
NZX flat on second trading day of 2025
Finance

M&A outlook: get set for big ticket IPOs

Experts are picking a surge in mergers and acquisitions activity for 2025.

M&A outlook: get set for big ticket IPOs